First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by …
C Gridelli, F Ciardiello, R Feld, CA Butts… - Journal of Clinical …, 2010 - ascopubs.org
7508 Background: In a placebo-controlled trial, E prolonged survival of unselected aNSCLC
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
patients (pts) not eligible for further chemotherapy. Two phase II studies suggested that first …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell …
8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
[HTML][HTML] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - Elsevier
Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and Erlotinib …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
相关搜索
- lung cancer cisplatin and gemcitabine
- lung cancer performance status
- lung cancer randomized phase
- erlotinib in combination cisplatin and gemcitabine
- lung cancer trial of erlotinib
- lung cancer standard chemotherapy
- lung cancer disease progression
- standard chemotherapy randomized phase
- lung cancer therapy in patients
- performance status randomized phase
- performance status trial of erlotinib
- trial of erlotinib randomized phase
- performance status standard chemotherapy
- standard chemotherapy trial of erlotinib
- paclitaxel chemotherapy erlotinib hydrochloride
- disease progression maintenance erlotinib